Induction of Protection in Mice against a Chlamydia muridarum Respiratory Challenge by a Vaccine Formulated with the Major Outer Membrane Protein in Nanolipoprotein Particles
Open Access
- 7 July 2021
- Vol. 9 (7), 755
- https://doi.org/10.3390/vaccines9070755
Abstract
Chlamydia trachomatis is a sexually transmitted bacterium that infects over 130 million individuals worldwide annually. To implement a vaccine, we developed a cell-free co-translational system to express the Chlamydia muridarum major outer membrane protein (MOMP). This approach uses a nanolipoprotein particles (tNLP) made from ApoA1 protein, amphiphilic telodendrimer and lipids that self-assemble to form 10–25 nm discs. These tNLP provide a protein-encapsulated lipid support to solubilize and fold membrane proteins. The cell-free system co-translated MOMP and ApoA1 in the presence of telodendrimer mixed with lipids. The MOMP-tNLP complex was amenable to CpG and FSL-1 adjuvant addition. To investigate the ability of MOMP-tNLP+CpG+FSL-1 to induce protection against an intranasal (i.n.) C. muridarum challenge, female mice were vaccinated intramuscularly (i.m.) or i.n. and i.m. simultaneously 4 weeks apart. Following vaccination with MOMP-tNLP+CpG+FSL-1, mice mounted significant humoral and cell-mediated immune responses. Following the i.n. challenge, mice vaccinated with MOMP-tNLP+CpG+FSL-1 i.n. + i.m. group were protected as determined by the percentage change in body weight and by the number of C. muridarum inclusion forming units (IFU) recovered from the lungs. To our knowledge, this is the first time a MOMP-based vaccine formulated in tNLP has been shown to protect against C. muridarum.Funding Information
- U.S. Public Health Service (R21 AI20925, U19AI144184)
- U.S. Department of Energy (DE-AC52-07NA27344)
This publication has 70 references indexed in Scilit:
- A TLR2 agonist is a more effective adjuvant for a Chlamydia major outer membrane protein vaccine than ligands to other TLR and NOD receptorsVaccine, 2011
- Induction of protection against vaginal shedding and infertility by a recombinant Chlamydia vaccineVaccine, 2011
- Amphipols stabilize the Chlamydia major outer membrane protein and enhance its protective ability as a vaccineVaccine, 2011
- Vaccination againstChlamydiaGenital Infection Utilizing the MurineC. muridarumModelInfection and Immunity, 2011
- Enhancement of the protective efficacy of a Chlamydia trachomatis recombinant vaccine by combining systemic and mucosal routes for immunizationVaccine, 2010
- CD4+T Cells and Antibody Are Required for Optimal Major Outer Membrane Protein Vaccine-Induced Immunity toChlamydia muridarumGenital InfectionInfection and Immunity, 2010
- Risk of Sequelae afterChlamydia trachomatisGenital Infection in WomenThe Journal of Infectious Diseases, 2010
- Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane proteinVaccine, 2009
- Vaccine adjuvants: scientific challenges and strategic initiativesExpert Review of Vaccines, 2009
- Intranasal Vaccination with a Secreted Chlamydial Protein Enhances Resolution of GenitalChlamydia muridarumInfection, Protects against Oviduct Pathology, and Is Highly Dependent upon Endogenous Gamma Interferon ProductionInfection and Immunity, 2007